In This Article:
As global markets navigate a mix of economic signals, with U.S. stocks closing out a strong year despite recent fluctuations and European inflation showing unexpected strength, investors are increasingly focused on stability and income generation. In this context, dividend stocks offer an attractive option for those seeking to enhance their portfolios by providing regular income and potential growth amidst the current market dynamics.
Top 10 Dividend Stocks
| Name | Dividend Yield | Dividend Rating |
| Tsubakimoto Chain (TSE:6371) | 4.22% | ★★★★★★ |
| CAC Holdings (TSE:4725) | 4.83% | ★★★★★★ |
| Padma Oil (DSE:PADMAOIL) | 7.41% | ★★★★★★ |
| GakkyushaLtd (TSE:9769) | 4.39% | ★★★★★★ |
| China South Publishing & Media Group (SHSE:601098) | 3.95% | ★★★★★★ |
| Nihon Parkerizing (TSE:4095) | 3.89% | ★★★★★★ |
| HUAYU Automotive Systems (SHSE:600741) | 4.44% | ★★★★★★ |
| FALCO HOLDINGS (TSE:4671) | 6.35% | ★★★★★★ |
| E J Holdings (TSE:2153) | 3.84% | ★★★★★★ |
| Banque Cantonale Vaudoise (SWX:BCVN) | 5.01% | ★★★★★★ |
Click here to see the full list of 1981 stocks from our Top Dividend Stocks screener.
Let's explore several standout options from the results in the screener.
China Petroleum & Chemical
Simply Wall St Dividend Rating: ★★★★☆☆
Overview: China Petroleum & Chemical Corporation is an energy and chemical company involved in oil, gas, and chemical operations in Mainland China, Singapore, and internationally with a market cap of HK$784.89 billion.
Operations: China Petroleum & Chemical Corporation's revenue segments include Refining at CN¥1.52 billion, Chemicals at CN¥528.87 million, Exploration and Production at CN¥304.40 million, and Marketing and Distribution at CN¥1.77 billion.
Dividend Yield: 8.2%
China Petroleum & Chemical's dividend yield of 8.23% ranks in the top 25% of Hong Kong market payers, yet it faces challenges with sustainability as dividends are not well covered by free cash flows, indicated by a high cash payout ratio of 164.6%. Despite an increase in dividend payments over the past decade, they have been volatile, experiencing significant annual drops. Recent earnings showed a decline in net income and revenue compared to last year.
TTY Biopharm
Simply Wall St Dividend Rating: ★★★★★☆
Overview: TTY Biopharm Company Limited, along with its subsidiaries, focuses on the development and sale of pharmaceutical and chemical drugs both in Taiwan and internationally, with a market cap of NT$18.28 billion.
Operations: TTY Biopharm's revenue is primarily derived from its Cancer Drug Business Group (NT$2.44 billion), Anti-infection Medicine Segment (NT$1.05 billion), Reinvestment Segment (NT$1.13 billion), Export and OEM Group (NT$981.22 million), and Healthcare Business Group (NT$562.90 million).